Generalized Likelihood Ratio Statistics and Uncertainty Adjustments in
  Efficient Adaptive Design of Clinical Trials by Bartroff, Jay & Lai, Tze Leung
ar
X
iv
:1
10
5.
46
67
v1
  [
ma
th.
ST
]  
24
 M
ay
 20
11
Generalized Likelihood Ratio Statistics and Uncertainty
Adjustments in Efficient Adaptive Design of Clinical Trials
Jay Bartroff
Department of Mathematics, University of Southern California, Los Angeles, CA, USA
Tze Leung Lai
Department of Statistics, Stanford University, Stanford, CA, USA
Abstract: A new approach to adaptive design of clinical trials is proposed in a general multi-
parameter exponential family setting, based on generalized likelihood ratio statistics and optimal
sequential testing theory. These designs are easy to implement, maintain the prescribed Type I
error probability, and are asymptotically efficient. Practical issues involved in clinical trials allow-
ing mid-course adaptation and the large literature on this subject are discussed, and comparisons
between the proposed and existing designs are presented in extensive simulation studies of their
finite-sample performance, measured in terms of the expected sample size and power functions.
Keywords. Hoeffding’s information bound; Internal pilot; Kullback-Leibler information; Modified
Haybittle-Peto test; Multiparameter exponential family; Sample size re-estimation
Subject Classifications. 62L10; 62F03; 62P10
Address correspondence to Jay Bartroff, Department of Mathematics, University of Southern California,
3620 South Vermont Ave., KAP 108, Los Angeles, CA 90089-2532, USA; E-mail: bartroff@usc.edu
1 INTRODUCTION
Because of the ethical and economic considerations in the design of clinical trials to test the
efficacy of new treatments and because of lack of information on the magnitude and sam-
pling variability of the treatment effect at the design stage, there has been increasing interest
from the biopharmaceutical industry in sequential methods that can adapt to information
acquired during the course of the trial. Beginning with Bauer (1989), who introduced sequen-
tial adaptive test strategies over a planned series of separate trials, and Wittes and Brittain
(1990), who discussed internal pilot studies, a large literature has grown on adaptive de-
sign of clinical trials. Depending on the topics covered, the term “adaptive design” in
this literature is sometimes replaced by “sample size re-estimation,” “trial extension” or
“internal pilot studies.” In standard clinical trial designs, the sample size is determined
by the power at a given alternative, but in practice, it is often difficult for investiga-
tors to specify a realistic alternative at which sample size determination can be based.
Although a standard method to address this difficulty is to carry out a preliminary pi-
lot study, the results from a small pilot study may be difficult to interpret and apply,
as pointed out by Wittes and Brittain (1990), who proposed to treat the first stage of a
two-stage clinical trial as an internal pilot from which the overall sample size can be re-
estimated. The problem of sample size re-estimation based on observed treatment differ-
ence at some time before the prescheduled end of a clinical trial has attracted consider-
able attention during the past decade; see, e.g., Gould and Shih (1992), Herson and Wittes
(1993), Birkett and Day (1994), Denne and Jennison (1999, 2000), Jennison and Turnbull
(2000, Section 14.2), Shih (2001) and Whitehead et al. (2001). For normally distributed
outcome variables with known variances, Proschan and Hunsberger (1995), Fisher (1998),
Posch and Bauer (1999) and Shen and Fisher (1999) have proposed ways to adjust the test
statistics after mid-course sample size modification so that the Type I error probability is
maintained at the prescribed level. By making use of a generalization of the Neyman-Pearson
lemma, Tsiatis and Mehta (2003) showed that these adaptive tests of a simple null versus a
simple alternative hypothesis are inefficient because they are not based on likelihood ratio
statistics. Jennison and Turnbull (2003) gave a general weighted form of these test statis-
tics and demonstrated in simulation studies that the adaptive tests performed considerably
worse than group sequential tests. Jennison and Turnbull (2006a) recently introduced adap-
tive group sequential tests that choose the jth group size and stopping boundary on the basis
of the cumulative sample size nj−1 and the sample sum Snj−1 over the first j−1 groups, and
that are optimal in the sense of minimizing a weighted average of the expected sample sizes
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over a collection of parameter values subject to prescribed error probabilities at the null and
a given alternative hypothesis. They showed how the corresponding optimization problem
can be solved numerically by using the backward induction algorithms for “optimal sequen-
tially planned” designs developed by Schmitz (1993). Jennison and Turnbull (2006b) found
that standard (non-adaptive) group sequential tests with the first stage chosen optimally are
nearly as efficient as their optimal adaptive tests.
Except for Jennison and Turnbull’s optimal adaptive group sequential tests and the
extensions of the sample size re-estimation approach to group sequential testing considered
by Cui et al. (1999), Lehmacher and Wassmer (1999) and Denne and Jennison (2000), previ-
ous works in the literature on mid-course sample size re-estimation have focused on two-stage
designs whose second-stage sample size is determined by the results from the first stage (in-
ternal pilot), following the seminal work of Stein (1945) in this area. Although this approach
is intuitively appealing, it does not adjust for the uncertainty in the first-stage parameter
estimates that are used to determine the second-stage sample size. Moreover, it considers
primarily the special problem of comparing the means of the two normal populations, using
the central limit theorem for extensions to more general situations. The case of unknown
common variance at a prespecified alternative for the mean difference was considered first,
as in Stein (1945) and the first set of references in the preceding paragraph. Then the case
of known variances in the absence of a prespecified alternative for the mean difference was
studied, as in the second set of references above.
Bartroff and Lai (2008) recently gave a unified treatment of both cases in the general
framework of multiparameter exponential families. It uses efficient generalized likelihood
ratio (GLR) statistics in this framework and adds a third stage to adjust for the sampling
variability of the first-stage parameter estimates that determine the second-stage sample
size. Specifically, let X1, X2, . . . be independent d-dimensional random vectors from a mul-
tiparameter exponential family fθ(x) = exp{θ′x − ψ(θ)} of densities with respect to some
measure ν on Rd. Let Sn = X1 + . . . + Xn. A sufficient statistic based on (X1, . . . , Xn)
is the sample mean X¯n = Sn/n, which is the maximum likelihood estimate of the mean
∇ψ(θ). Consider the hypothesis u(θ) = uj, where j = 0 or 1, u : Θ → R is continuously
differentiable and Θ = {θ : ∫ eθ′xdν(x) < ∞} is the natural parameter space. As noted by
Lai and Shih (2004, p. 513), the GLR statistic Λi,j for total sample size ni at stage i has the
form
Λi,j = ni{θ̂′niX¯ni − ψ(θ̂ni)} − sup
θ:u(θ)=uj
ni{θ′X¯ni − ψ(θ)} = inf
θ:u(θ)=uj
niI(θ̂ni , θ), (1.1)
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in which θ̂n = (∇ψ)−1(Xn) and I(θ, λ) is the Kullback-Leibler information number given by
I(θ, λ) = Eθ[log{fθ(Xi)/fλ(Xi)}] = (θ − λ)′∇ψ(θ)− {ψ(θ)− ψ(λ)}. (1.2)
The possibility of adding a third stage to improve two-stage designs dated back to Lorden
(1983). Whereas Lorden used crude upper bounds for the Type I error probability that are
too conservative for practical applications, Bartroff and Lai (2008) overcome this difficulty
by developing numerical methods to compute the Type I error probability, and also extended
the three-stage test to multiparameter and multi-armed settings, thus greatly broadening the
scope of these efficient adaptive designs. A review of their method is given in Section 2.1. In
Section 4 we prove the asymptotic optimality of these adaptive tests in the multiparameter
case, extending Lorden’s (1983) result for the special case d = 1.
Another new addition to this asymptotic optimality theory of adaptive designs is related
to the problem of trial extension considered in Section 2.2. As pointed out by Cui et al.
(1999), the issue of increasing the maximum sample size sometimes arises after interim
analysis in group sequential trials. They cited a study protocol, which was reviewed by the
Food and Drug Administration, involving a Phase III group sequential trial for evaluating
the efficacy of a new drug to prevent myocardial infarction in patients undergoing coronary
artery bypass graft surgery. During interim analysis, the observed incidence for the drug
achieved a reduction that was only half of the target reduction assumed in the calculation of
the maximum sample size M , resulting in a proposal to increase the maximum sample size to
M˜ (Nmax in their notation). Cui et al. (1999) and Lehmacher and Wassmer (1999) extended
the sample size re-estimation approach to adaptive group sequential trials by adjusting the
test statistics as in Proschan and Hunsberger (1995) and allowing the future group sizes to
be increased or decreased during interim analyses so that the overall sample size does not
exceed M˜(> M) and the Type I error probability is maintained at the prescribed level. In
Section 2.2 we propose an alternative approach that is shown to be asymptotically efficient
in Section 4. Whereas the adaptive designs in Section 2.1 assume a given maximum sample
size M and require at most 3 stages, Section 2.2 extends them to allow mid-course increase
of M to M˜ . These adaptive designs involve no more than 4 stages and an adjustment in the
maximum sample size is made at the third stage. Computational algorithms to implement
them are provided in Section 2.3 and simulation results on their performance are given in
Section 3.4.
Bartroff and Lai (2008) carried out comprehensive simulation studies of the performance,
measured in terms of the expected sample size and power functions, of their adaptive test
3
and compared it with other adaptive tests in the literature. In the case of normal mean
with known variance and Type I and II error constraints under the null and a given al-
ternative hypothesis, they showed that their adaptive test is comparable to the benchmark
optimal adaptive test of Jennison and Turnbull (2006a,b), which is superior to the existing
two-stage adaptive designs. On the other hand, whereas the benchmark optimal adaptive
test needs to assume a specified alternative, these adaptive two-stage tests and the adap-
tive tests of Bartroff and Lai (2008) do not require such assumptions as they consider the
estimated alternative at the end of the first stage. In their recent survey of adaptive de-
signs, Burman and Sonesson (2006) pointed out that previous criticisms of the statistical
properties of two-stage adaptive designs may be unconvincing in some situations when flex-
ibility and not having to specify parameters that are unknown at the beginning of a trial
(like the relevant treatment effect or variance) are more imperative than efficiency or be-
ing powerful. The adaptive designs in Bartroff and Lai (2008) and this paper can fulfill
the seemingly disparate requirements of flexibility and efficiency on a design. Rather than
achieving exact optimality at a specified collection of alternatives through dynamic program-
ming, they achieve asymptotic optimality over the entire range of alternatives, resulting in
near-optimality in practice. They are based on efficient test statistics of the GLR type,
which have an intuitively “adaptive” appeal via estimation of unknown parameters by max-
imum likelihood, ease of implementation and freedom from having to specify the relevant
alternative; see Section 2.
Bauer and Einfalt (2006) have found from a search of the medical literature that adaptive
designs have not been widely used in practice and that “adaptations in practice are rather
limited to sample size reassessment.” Perhaps one reason why these two-stage adaptive de-
signs have not gained wide acceptance is their use of seemingly unnatural and convoluted
test statistics (e.g., the inefficient test statistics mentioned in the first paragraph). This can
be circumvented by the use of efficient GLR statistics in our adaptive tests with no more
than 3 (or 4) stages. Another reason may be the lack of routine medical studies to which
adaptive designs can lead to substantial improvements over current practice. In Section 3.1
we consider one such potential application in Phase II cancer studies. We show how our
adaptive designs offer improvements over Simon’s (1989) optimal two-stage designs, which
are commonly used in single-arm cancer trials, and over their analogs, due to Thall et al.
(1988), for randomized trials in Section 3.2. Section 3.3 considers another issue that often
arises in the design of clinical trials, namely, nuisance parameters. “Very often, statisti-
cal information also depends on nuisance parameters (e.g., the standard deviation of the
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response variable). Extension of statistical information is a design adaptation that occurs
most frequently” (Hung et al., 2006). The simulation results in Section 3.3 shows how our
adaptive test resolves the difficulties with conventional two-stage designs to treat nuisance
parameters, which are estimated at the end of the first stage and then used to estimate the
second stage sample size. Further discussion of our proposed approach to adaptive designs
and some concluding remarks are given in Section 5.
2 EFFICIENT ADAPTIVE DESIGN AND GLR TESTS
2.1 An Adaptive 3-Stage GLR Test
Whereas Tsiatis and Mehta (2003) consider the case of simple null and alternative hypothe-
ses θ = θj (j = 0, 1) for which likelihood ratio tests are most powerful even in their group
sequential designs, Bartroff and Lai (2008) use the GLR statistics (1.1) in an adaptive three-
stage test of the composite null hypothesis H0 : u(θ) ≤ u0, where u is a smooth real-valued
function such that
I(θ, λ) is increasing in u(λ) for every fixed θ. (2.1)
Let n1 = m be the sample size of the first stage (or internal pilot study) and n3 = M be the
maximum total sample size, both specified before the trial. Let u1 > u0 be the alternative
implied by the maximum sample size M and the reference Type II error probability α˜. That
is, u1(> u0) is the alternative where the fixed sample size (FSS) GLR test with Type I error
probability α and sample size M has power infθ:u(θ)=u1 Pθ{Reject H0} equal to 1 − α˜, as
in Lai and Shih (2004, Section 3.4). The three-stage test of H0 : u(θ) ≤ u0 stops and rejects
H0 at stage i ≤ 2 if
ni < M, u(θ̂ni) > u0 and Λi,0 ≥ b. (2.2)
Early stopping for futility (accepting H0) can also occur at stage i ≤ 2 if
ni < M, u(θ̂ni) < u1 and Λi,1 ≥ b˜. (2.3)
The test rejects H0 at stage i = 2 or 3 if
ni = M, u(θ̂M) > u0 and Λi,0 ≥ c, (2.4)
accepting H0 otherwise. The sample size n2 of the three-stage test is given by
n2 = m ∨ {M ∧ ⌈(1 + ρm)n(θ̂m)⌉} (2.5)
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with
n(θ) = min{| logα|/ inf
λ:u(λ)=u0
I(θ, λ), | log α˜|/ inf
λ:u(λ)=u1
I(θ, λ)}, (2.6)
where ρm > 0 is an inflation factor to adjust for uncertainty in θ˜m; see the examples in
Section 3. Letting 0 < ε, ε˜ < 1, define the thresholds b, b˜ and c to satisfy the equations
sup
θ:u(θ)=u1
Pθ{(2.3) occurs for i = 1 or 2} = ε˜α˜, (2.7)
sup
θ:u(θ)=u0
Pθ{(2.3) does not occur for i ≤ 2, (2.2) occurs for i = 1 or 2} = εα, (2.8)
sup
θ:u(θ)=u0
Pθ{(2.2) and (2.3) do not occur for i ≤ 2, (2.4) occurs} = (1− ε)α. (2.9)
The probabilities in (2.7)-(2.9) can be computed by using the normal approximation to the
signed-root likelihood ratio statistic
ℓi,j = {sign(u(θ̂ni)− uj)}(2niΛi,j)1/2,
(1 ≤ i ≤ 3 and j = 0, 1) under u(θ) = uj, as in Lai and Shih (2004, p. 513). When u(θ) = uj,
ℓi,j is approximately normal with mean 0, variance ni, and the increments ℓi,j − ℓi−1,j are
asymptotically independent. We can therefore approximate ℓi,j by a sum of independent
standard normal random variables under u(θ) = uj and thereby determine b, b˜ and c. Note
that this normal approximation can also be used for the choice of u1 implied by M and α˜.
Computational details are given in Section 2.3, as well as an alternate method for computing
the thresholds by Monte Carlo.
A special multiparameter case of particular interest in clinical trials involves K in-
dependent populations having density functions exp{θkx − ψ˜k(θk)} so that θ′x − ψ(θ) =∑K
k=1{θkxk − ψ˜(θk)}. In multi-armed trials, for which different numbers of patients are as-
signed to different treatments, the GLR statistic Λi,j for testing the hypothesis u(θ1, . . . , θK) =
uj (j = 0 or 1) at stage i has the form
Λi,j =
K∑
k=1
nki{θ̂k,nkiXk,nki − ψ˜(θ̂k,nki)} − sup
θ:u(θ1,...,θK)=uj
K∑
k=1
nki{θkXk,nki − ψ˜(θk)},
in which nki is the total number of observations from the kth population up to stage i.
Let ni =
∑K
k=1 nki. As pointed out in Section 3.4 of Lai and Shih (2004), the normal
approximation to the signed root likelihood ratio statistic is still applicable when nki =
pkni + Op(n
1
2
i ), where p1, . . . , pK are nonnegative constants that sum up to 1, as in random
allocation of patients to the K treatments (for which pk = 1/K).
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2.2 Mid-course Modification of Maximum Sample Size
We now modify the adaptive designs in the preceding section to accommodate the possibility
of mid-course increase of the maximum sample size from M to M˜ . Let u2 be the alternative
implied by M˜ so that the level-α GLR test with sample size M˜ has power 1− α˜. Note that
u1 > u2 > u0. Whereas the sample size n3 is chosen to be M in Section 2.1, we now define
n˜(θ) = min{| logα|/ inf
λ:u(λ)=u0
I(θ, λ), | log α˜|/ inf
λ:u(λ)=u2
I(θ, λ)},
n3 = n2 ∨ {M ′ ∧ ⌈(1 + ρm)n˜(θ̂n2)⌉},
where M < M ′ ≤ M˜ and n2 = m ∨ {M ∧ (1 + ρm)n˜(θ̂m)}. We can regard the test as a
group sequential test with 4 groups and n1 = m, n4 = M˜ , but with adaptively chosen n2 and
n3. If the test does not end at the third stage, continue to the fourth and final stage with
sample size n4 = M˜ . Its rejection and futility boundaries are similar to those in Section 2.1.
Extending our notation Λi,j in (1.1) to 1 ≤ i ≤ 4 and 0 ≤ j ≤ 2, the test stops at stage i ≤ 3
and rejects H0 if
ni < M˜, u(θ̂ni) > u0, and Λi,0 ≥ b, (2.10)
stops and accepts H0 if
ni < M˜, u(θ̂ni) < u2, and Λi,2 ≥ b˜, (2.11)
and rejects H0 at stage i = 3 or 4 if
ni = M˜, u(θ̂M˜) > u0, and Λi,0 ≥ c, (2.12)
accepting H0 otherwise. The thresholds b, b˜ and c can be defined by equations similar to
(2.7)-(2.9) to insure the overall Type I error probability to be α. For example, in place of
(2.7),
sup
θ:u(θ)=u2
Pθ{(2.11) occurs for some i ≤ 3} = ε˜α˜. (2.13)
The basic idea underlying (2.13) is to control the Type II error probability at u2 so that the
test does not lose much power there in comparison with the GLR test that has sample size
M˜ (and therefore power 1− α˜ at u2).
2.3 Implementation via Normal Approximation or Monte Carlo
To begin with, suppose the Xi are N(θ, 1) and u(θ) = θ. We write θj instead of uj and,
without loss of generality, we shall assume that θ0 = 0. The thresholds b, b˜ and c of the
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three-stage test in Section 2.1 can be computed by solving in succession (2.7), (2.8) and
(2.9). Univariate grid search or Brent’s method (Press et al., 1992) can be used to solve
each equation. Since I(θ, λ) = (θ − λ)2/2, we can rewrite (2.7) as
Pθ1{Sm −mθ1 > −(2b˜m)
1
2 , Sn2 − n2θ1 ≤ −(2b˜n2)
1
2}+ Pθ1{Sm −mθ1 ≤ −(2b˜m)1/2} = ε˜α˜,
and (2.8) and (2.9) as
P0{Sm/(2m) 12 ≥ b 12}+ P0{b˜ 12 < Sm/(2m) 12 < b 12 , Sn2/(2n2)
1
2 ≥ b 12 , n2 < M} = εα,
P0{b˜ 12 < Sm/(2m) 12 < b 12 , n2 < M, b˜ 12 < Sn2/(2n2)
1
2 < b
1
2 , SM/(2M)
1
2 ≥ c 12}
+P0{b˜ 12 < Sm/(2m) 12 < b 12 , n2 =M,SM/(2M) 12 ≥ c 12} = (1− ε)α.
The probabilities involving n2 can be computed by conditioning on the value of Sm/m, which
completely determines the value of n2, denoted by k(x). For example, the probabilities under
θ = 0 can be computed via
P0{Sn2 ≥ (2bn2)
1
2 |Sm = mx} = P{N(0, 1) ≥ [2bk(x)n
1
2
2 −mx]/[k(x) −m]
1
2},(2.14)
P0{Sn2 ∈ dy, SM ∈ dz|Sm = mx} = ϕk(x)−m(y −mx)ϕM−k(x)(z − y)dydz, (2.15)
where ϕv is the N(0, v) density function, i.e., ϕv(w) = (2πv)
− 1
2 exp(−w2/2v). The proba-
bilities under θ1 can be computed similarly. Hence standard recursive numerical integration
algorithms can be used to compute the probabilities in (2.7)-(2.9); see Jennison and Turnbull
(2000, Section 19.2). For the general multiparameter exponential family, this method can be
used to compute the thresholds b, b˜ and c for (2.2)-(2.4) since the problem can be approxi-
mated by that of testing a normal mean, as discussed in Section 2.1.
For mid-course modification of the maximum sample size in Section 2.2, the above
recursive numerical algorithm can be modified to handle the randomness of n2 and n3. The
basic idea is that conditional on Sm/m = x, the value of n2 is completely determined as k(x),
and conditional on Sm/m = x and Sn2/n2 = y, the value of n3 is completely determined as
h(x, y). Therefore, analogous to (2.15), we now have
P{Sn3 ∈ du, SM˜ ∈ dw|Sm/m = x, Sn2/n2 = y}
= ϕh(x,y)−k(x)(u− yk(x))ϕM˜−h(x,y)(w − u)dudw, (2.16)
and can use bivariate recursive numerical integration. For the general exponential family,
normal approximation to the signed-root likelihood ratio statistic can again be used.
An alternative to normal approximation is to use Monte Carlo similar to that used
in bootstrap tests. While using Monte Carlo simulations to compute error probabilities is
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an obvious idea, it is far from being clear which distribution from a composite hypothesis
should be chosen to simulate from. Bootstrap theory suggests that we can simulate from the
estimated distribution under the assumed hypothesis as the GLR statistic is an approximate
pivot under that hypothesis. Since the “estimated distribution” needs data to arrive at the
estimate, we make use of the first-stage data to determine b and b˜, then we use the second-
stage data to determine c for the three-stage test in Section 2.1. Specifically, the Monte Carlo
method to determine b, b˜ and c proceeds as follows. At the end of the first stage, compute
the maximum likelihood estimate θ̂m,j under the constraint u(θ) = uj, j = 0, 1. Determine
b˜, b and c successively by solving
Pθ̂m,1{(2.3) occurs for i = 1 or 2} = ε˜α˜, (2.17)
Pθ̂m,0{(2.3) does not occur for i ≤ 2, and (2.2) occurs for i = 1 or 2} = εα, (2.18)
Pθ̂n2,0
{(2.2) and (2.3) do not occur for i ≤ 2, and (2.4) occurs} = (1− ε)α, (2.19)
noting that c does not have to be determined until after the second stage when n2 observations
become available for the updated estimate θ̂n2,0. The probabilities in (2.17)-(2.19), with
θ = θ̂m,1 or θ = θ̂m,0 as indicated, can be computed by Monte Carlo simulations. Similarly,
to determine thresholds b, b˜ and c of the adaptive test in Section 2.2, we can use Monte
Carlo simulations instead of normal approximation and numerical integration to compute
the corresponding probabilities.
3 APPLICATIONS AND NUMERICAL EXAMPLES
3.1 Application to Single-Arm Phase II Cancer Trials
As pointed out by Vickers et al. (2007, p. 927), in a typical phase II study of a novel cancer
treatment, “a cohort of patients is treated, and the outcomes are related to the prespecified
target or bar. If the results meet or exceed the target, the treatment is declared worthy of
further study; otherwise, further development is stopped. This has been referred to as the
‘go/ no go’ decision. Most often, the outcome specified is a measure of tumor response, e.g.,
complete or partial response using Response Evaluation Criteria in Solid Tumors, expressed
as a proportion of the total number of patients. Response can also be defined in terms of
the proportion who have not progressed or who are alive at a predetermined time (e.g., one
year) after treatment is started.” The most widely used designs for these single-arm phase II
trials are Simon’s (1989) optimal 2-stage designs, which allow early stopping of the trial if
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the treatment has not shown beneficial effect that is measured by a Bernoulli proportion.
These designs are optimal in the sense of minimizing the expected sample size under the null
hypothesis of no viable treatment effect, subject to Type I and II error probability bounds.
Given a maximum sample sample size M , Simon considered the design that stops for futility
afterm < M patients if the number of patients exhibiting positive treatment effect is r1(≤ m)
or fewer, and otherwise treats an additional M − m patients and rejects the treatment if
and only if the number of patients exhibiting positive treatment effect is r2(≤ M) or fewer.
Simon’s designs require that a null proportion p0, representing some “uninteresting” level
of positive treatment effect, and an alternative p1 > p0 be specified. The null hypothesis is
H0 : p ≤ p0, where p denotes the probability of positive treatment effect. The Type I and II
error probabilities Pp0{Reject H0}, Pp1{Accept H0} and the expected sample size Ep0N can
be computed for any design of this form, which can be represented by the parameter vector
(m,M, r1, r2). Using computer search over these integer-valued parameters, Simon (1989)
tabulated the optimal designs in his Tables 1 and 2 for different values of (p0, p1).
Whether the new treatment is declared promising in a phase II trial depends strongly
on the prescribed p0 and p1. In their systematic review of 134 papers reporting phase II
trials in J. Clin. Oncology, Vickers et al. (2007) found 70 papers referring to historical data
for their choice of the null or alternative response rate, and that nearly half (i.e., 32) of these
papers did not cite the source of the historical data used, while only 9 gave clearly a single
historical estimate of their choice of p0. Moreover, no study “incorporated any statistical
method to account for the possibility of sampling error or for differences in case mix between
the phase II sample and the historical cohort.” The adaptive designs in Section 2.1 applied
to this setting do not require the specification of the alternative p1, a desirable property to
prevent well-intentioned but misguided practitioners from choosing p1 artificially small to
inflate the appearance of a positive treatment effect, if one exists; uncertainty in the choice
of p0 is also an important issue and is addressed in Section 3.2. For now, assume p0 to be
given along with initial and maximum sample sizes m and M . The adaptive test takes p1
to be the alternative where the FSS test, with Type I error probability α at p0, has power
1 − β, i.e., the solution of FM,p1(F−1M,p0(1 − α)) = β, where FM,p is the distribution function
of the Bin(M, p) distribution. The GLR statistic (1.1) at the ith stage is
ni
[
p̂ni log
(
p̂ni
pj
)
+ (1− p̂ni) log
(
1− p̂ni
1− pj
)]
for j = 0 or 1, and the critical values b, b˜ and c are chosen to satisfy (2.7)-(2.9). Because of
discreteness of the binomial distribution it may be impossible to satisfy (2.7)-(2.9) exactly,
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Table 1. Description of ADAPT and Sim2 for two cases
Sm ADAPT Sim2 (p1 = .3 or .44)
(a) m = 10, M = 29, p0 = .1, α = .05, β = .2
≤ 1 Accept H0. Accept H0.
2 n2 = M ; reject H0 if Sn2 ≥ 6. n2 =M and
3 n2 = 20 reject H0 if SM ≥ 6.
(i) If Sn2 ≤ 3, accept H0.
(ii) If Sn2 ≥ 6, reject H0.
(iii) If 4 ≤ Sn2 ≤ 5 and SM ≥ 6, reject H0.
≥ 4 Reject H0. n2 =M ; rej. H0 if SM ≥ 6.
(b) m = 30, M = 82, p0 = .1, α = β = .1
≤ 8 Accept H0. Accept H0.
9 n2 = 57 Accept H0.
(i) If Sn2 ≤ 19, accept H0.
(ii) If Sn2 ≥ 24, reject H0.
(iii) If 20 ≤ Sn2 ≤ 23 and SM ≥ 32, reject H0.
10− 13 n2 = M ; reject H0 if Sn2 ≥ 31. n2 =M and
≥ 14 Reject H0. reject H0 if SM ≥ 30.
in which case (2.7) is satisfied approximately and (2.8)-(2.9) are satisfied conservatively. The
stopping rule defined by (2.2)-(2.4) may alternatively be stated in terms of the number of
cumulative successes Sni at the ith stage. Table 1 describes the adaptive design (denoted by
ADAPT) and Simon’s (1989) optimal 2-stage design (denoted by Sim2) for two choices of
m,M, α, β, p0 and Table 2 contains their operating characteristics, computed exactly using
the Bin(n, p) distribution. ADAPT has expected sample size close to Sim2 for p near p0, and
smaller sample size when p is roughly midway between p0 and p1 or is larger; p1 = .3 in the
top panel of Table 2 and p1 = .44 in the bottom panel. It is not surprising that the expected
sample size of Sim2 increases with p since Sim2 only stops early for futility. The expected
number of stages shows a similar pattern, while their power functions are nearly identical.
Note that even though ADAPT has a maximum of three stages, its expected number of
stages is less than 2 for all p and usually close to 1.
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Table 2. Expected sample size, power (in parentheses) and expected number of stages (in
brackets) of phase II designs
p ADAPT Sim2
(a) m = 10, M = 29, p0 = .1, α = .05, β = .2
.05 11.6 (.3%) [1.1] 11.6 (.2%) [1.1]
p0 = .1 14.5 (5%) [1.3] 15.0 (4.7%) [1.3]
.2 18.8 (43.3%) [1.6] 21.9 (43.1%) [1.6]
p1 = .3 18.1 (79.4%) [1.6] 26.1 (79.6%) [1.8]
.4 14.8 (94.9%) [1.4] 28.1 (95.0%) [2.0]
.5 12.1 (98.9%) [1.2] 28.8 (98.9%) [2.0]
.6 10.1 (99.9%) [1.0] 29.0 (99.9%) [2.0]
(b) m = 30, M = 82, p0 = .3, α = β = .1
.2 34.9 (.3%) [1.1] 33.2 (.03%) [1.1]
p0 = .3 51.8 (10.0%) [1.5] 51.4 (10.0%) [1.4]
.35 60.4 (35.0%) [1.7] 63.4 (36.2%) [1.6]
p1 = .44 52.9 (88.7%) [1.5] 77.7 (87.8%) [1.9]
.5 42.4 (98.4%) [1.3] 80.9 (97.5%) [2.0]
.6 31.9 (99.9%) [1.0] 82.0 (99.9%) [2.0]
3.2 Extension to Randomized Phase II Cancer Trials
As noted by Vickers et al. (2007), uncertainty in the choice of p0 and p1 can increase the
likelihood that (a) a treatment with no viable positive treatment effect proceeds to phase III,
or (b) a treatment with positive treatment effect is abandoned at phase II. To circumvent the
problem of choosing an artificially small p0, either intentionally by a practitioner wanting to
give the treatment the “best chance” of showing a positive effect if one exists, or unintention-
ally because of inaccurate information about the control, Ellenberg and Eisenberger (1985)
proposed to perform a controlled 2-arm phase II trial in which patients are randomized into
both treatment and control groups. After randomizing 2n1 patients into treatment and con-
trol arms, the trial is stopped for futility when the number in the treatment group showing
positive effect is not greater than in the control group. Otherwise, the trial continues until a
total of 2n2 patients have been randomized into the study and then a standard fixed sample
binomial test is performed. Letting p and q denote the probability of positive effect in the
treatment and control groups, respectively, Thall et al. (1988) subsequently chose n1, n2 and
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two other design parameters y1 and y2, described below, to minimize the “average” expected
sample size
AvSS =
1
2
[E(N |p = q) + E(N |p = q + δ)] (3.1)
subject to Type I and II error probability constraints α and β. The two-stage test of
H0 : p ≤ q stops for futility after the first stage if an approximately normally distributed
test statistic Z1, based on the 2-population binomial data, is no greater than y1, otherwise
continuing with a second stage and rejecting H0 if Z2 > y2. Because the expectations in
(3.1) depend on p and q, both must be specified to calculate the trial design.
The adaptive designs of Section 2 apply naturally to this 2-arm setting. The GLR
statistic (1.1) at the ith stage is
ni
[
p̂i log
(
p̂i
p̂δj
)
− (1− p̂i) log
(
1− p̂i
1− p̂δj
)
+ q̂i log
(
q̂i
p̂δj − δj
)
− (1− q̂i) log
(
1− q̂i
1− p̂δj + δj
)]
,
where p̂i, q̂i are the fraction of successes in the treatment and control arms and p̂δj is the
MLE of p under p− q = δj, j = 0, 1, where δ0 = 0 and δ1 is the implied alternative (see the
example below). The boundaries b, b˜ and c can be computed using a normal approximation
or Monte Carlo simulations as described in Section 2.3; the latter, with 1 million simulations
for each probability calculation, is used in the following comparative study.
Thall and Simon (1994) describe a phase II trial of fludarabine + ara-C + granulocyte
colony stimulating factor (G-CSF) for treatment of acute myelogenous leukemia (AML).
Although this trial was designed using other methods described in their paper, we use it
here as a real setting to compare the adaptive design with Thall et al.’s (1988) design. The
standard therapy for AML at the time was fludarabine + ara-C alone, and in a preceding
study, 22 out of 45 patients achieved complete remission of the leukemia, the clinical endpoint
of interest, suggesting an initial estimate of q of .5. The study was conducted to detect an
increase in remission rate of δ = .2. For α = .05 and β = .2, Thall et al.’s (1988) optimal 2-
stage design (denoted by Opt2) for detecting a 20% improvement when the control remission
rate q is .5 has first stage of 33 per arm, followed by a second stage of 45 per arm if Z1 >
y1 = .356, and rejecting the null hypothesis after the second stage if Z2 > y2 = 1.584. The
adaptive design (denoted by ADAPT) with first stage m = 25 and maximum sample 78 per
arm, the same as Opt2, uses boundaries b = 2.12, b˜ = 1.03 and c = 1.56 for α = .05, α˜ = .2
and ε = ε˜ = 1/2. Table 3 contains the operating characteristics of ADAPT and Opt2 for
a variety of treatment and control response rates (p, q) around (.7, .5). Each result is based
on 100,000 simulations. ADAPT has substantially smaller expected sample size than Opt2.
This is in part because Opt2 only stops early for futility, although the parameters of Opt2
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Table 3. Expected sample size, power (in parentheses), expected number of stages (in
brackets) and average expected sample size (3.1) (denoted by AvSS) of 2-arm phase II
designs
q p ADAPT Opt2
.4 .3 33.3 (0.4%) [1.1] 37.8 (0.2%) [1.1]
.4 46.1 (5.3%) [1.5] 48.9 (5.3%) [1.4]
.5 57.5 (32.3%) [1.8] 63.3 (35.6%) [1.7]
.6 56.4 (76.0%) [1.8] 73.5 (78.9%) [1.9]
.7 43.8 (97.0%) [1.5] 77.3 (97.7%) [2.0]
AvSS 51.3 61.2
.5 .4 34.7 (0.4%) [1.2] 38.2 (0.2%) [1.1]
.5 47.3 (5.0%) [1.5] 49.0 (5.6%) [1.4]
.6 57.5 (32.2%) [1.8] 63.3 (35.5%) [1.7]
.7 55.1 (77.8%) [1.8] 73.7 (80.4%) [1.9]
.8 41.0 (97.6%) [1.4] 77.5 (98.2%) [2.0]
AvSS 51.2 61.4
.6 .5 34.7 (0.4%) [1.2] 38.2 (0.2%) [1.1]
.6 46.0 (5.2%) [1.5] 48.9 (5.3%) [1.4]
.7 55.8 (33.2%) [1.7] 63.3 (35.6%) [1.7]
.8 52.3 (81.1%) [1.7] 74.4 (84.2%) [1.9]
.9 35.9 (98.5%) [1.3] 77.8 (99.4%) [2.0]
AvSS 49.2 61.7
in this case are chosen to minimize (3.1), yet there is substantial savings both when p = q
and p = q + δ. ADAPT and Opt2 have similar expected number of stages near the null
hypothesis, with ADAPT decreasing as p − q increases while Opt2 steadily increases to 2,
again due to its early stopping only for futility. The power functions of the tests are similar,
with Opt2 having slightly higher power. Note that the Type I error probability of Opt2
is inflated above α = .05 at p = q = .5 due to the normal approximations to Zi used to
compute the design parameters.
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3.3 Comparison with Adaptive Tests for Difference of Means with
Unknown Variances
Let X1, X2, . . . and Y1, Y2, . . . be independent normal observations with unknown means
µX , µY and variances σ
2
X , σ
2
Y , respectively. Even if the variances σ
2
X , σ
2
Y are assumed equal,
no fixed sample size test of the hypothesis µX ≤ µY can achieve specified error probabilities
α, α˜ at µX − µY equal to 0 and some specified δ > 0 without knowing the true value of the
variance, as demonstrated by Dantzig (1940). To overcome this difficulty in the case of a
single normal mean, Stein (1945) proposed a two-stage procedure that uses the first-stage
sample to estimate the variance. The total sample size is then determined as a function of
this estimate so that the test statistic, which uses the data from both stages to estimate
the mean but only the first stage to estimate the variance, is exactly t-distributed under
µX − µY = 0 at which the test has Type I error α; the power of the test at µX − µY = δ is
strictly larger than 1 − α˜. Stein’s procedure can be easily extended to the mean difference
problem if σ2X = σ
2
Y , and has been modified for clinical trials by Wittes and Brittain (1990),
Birkett and Day (1994), and Denne and Jennison (1999). These modifications of Stein’s
procedure use the overall sample to estimate both the mean difference and the common
variance in modifying Stein’s test statistic, and therefore may not maintain the Type I error
probability at the prescribed level. Wittes and Brittain (1990) also assume a prior estimate
σ20 (e.g., from previous studies in the literature) of the common variance to modify Stein’s
formula for the total sample size.
In Table 4 we compare the performance of the adaptive test in Section 2.1 (denoted by
ADAPT) with Stein’s test, denoted by S, and the modified versions of Wittes and Brittain
(1990, denoted by WB), Birkett and Day (1994, denoted by BD) and Denne and Jennison
(1999, denoted by DJ) in the context of a phase II hypercholesterolaemia treatment efficacy
trial described by Facey (1992). In this trial, patients were randomized into treatment and
placebo groups and serum cholesterol level reductions, Xi and Yi, assumed to be normally
distributed, were measured after four weeks of treatment. A difference in reductions of serum
cholesterol levels, in mmol/liter, between the treatment and placebo groups of 1.2 was of
clinical interest. Based on previous studies, it was anticipated that the standard deviation
of the reductions would be about 0.7 for both groups. If the standard deviation were known
to be σ0 = 0.7, the size of the fixed sample t-test with error probabilities α = α˜ = .05 at
mean difference 0 and δ = 1.2 is 9 per group. Following Denne and Jennison (1999), we
assume a first-stage per-group sample size of m = 5, being approximately half of 9. If the
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standard deviation were in fact 2σ0 = 1.4, the per-group sample size of the same t-test is
31, which we take as a reasonable maximum sample size M for our three-stage test with
ρm = .1 and ε = ε˜ = 1/3. Table 4 contains the power and per-group expected sample
size of ADAPT and the aforementioned procedures in the literature, evaluated by 100,000
simulations at various values of µX − µY ∈ [0, δ] and σ = σX = σY . Whereas the Stein-type
tests require this assumption of equal variances, the three-stage tests defined in Section 2.1
do not, so for comparison we also include in Table 4 the three-stage test that does not
assume σX = σY , which we denote by ADAPT6=. The Kullback-Leibler information number
I = min{I((µX, µY , σ2), (µ˜X, µ˜Y , σ˜2)) : µ˜X− µ˜Y = 0}, where I(θ, θ˜) is defined in (1.2), is also
reported in the first column. When the true standard deviations σX and σY are equal to the
specified value σ0, ADAPT and ADAPT6= have similar power but smaller expected sample
size than the other tests for values of µX − µY near 0 and δ. When the standard deviations
σX and σY are larger than the specified value σ0, the adaptive tests have much smaller
expected sample sizes than the Stein-type tests, whose second-stage sample size increases
without bound as a function of the first-stage sample variance; in particular, see the last
three rows of Table 4.
An alternative approach to Stein-type designs has been used by Proschan and Hunsberger
(1995) and Li et al. (2002), who simply replace the σ2 in their two-stage tests that assume
known variance with its current estimate at each stage. To compare ADAPT with these
tests, which rely on stable variance estimates, we allow a larger first-stage sample size of
m = 20. Table 5 contains the power and per-group expected sample size of Proschan &
Hunsberger’s test (denoted by PH), two choices of the early stopping boundaries (h, k) in
Table 1 of Li et al. (2002) for their test, which we denote by L1 and L2, and our three-stage
test ADAPT, for various values of µX − µY and σ, each entry being the result of 100,000
replications. To compare these tests on equal footing we have chosen the maximum sample
sizeM = 121 for ADAPT because this is the maximum sample size of L1 and is quite close to
the maximum sample sizes of PH and L2, which are 122 and 104, respectively. The PH, L1
and L2 tests are designed to achieve Type I error probability .05 and they choose the sample
size of their second stage based on a conditional power level of 80%. The threshold values
b = 2.68, b˜ = 1.75, c = 1.75 used by ADAPT are thus computed using α = .05, α˜ = .20. The
results in Table 5 show that the true power of L1, L2 and PH falls well below their nominal
conditional power level of 80%. When σ = 2, the L1, L2 and PH tests have power less
than 50% for all values of µX − µY considered, which is caused by stopping prematurely for
futility at the end of the first stage; see in particular the rows in Table 5 that correspond to
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Table 4. Power and per-group expected sample size of tests of H0 : µX ≤ µY
(µX − µY , σ)
I
S WB BD DJ ADAPT ADAPT6=
(0, σ0/2) 5.0% 4.9% 5.0% 5.0% 1.6% 1.8%
I = 0 5.0 9.0 5.0 5.0 5.0 5.0
(0, σ0) 5.0% 5.4% 6.0% 5.6% 4.0% 4.1%
I = 0 10.1 10.1 10.1 10.3 9.4 10.2
(δ/2, σ0) 53.0% 59.5% 55.4% 57.3% 65.0% 68.1%
I = .169 10.1 10.1 10.1 10.3 15.5 13.7
(δ, σ0) 96.6% 98.0% 95.8% 96.4% 97.8% 98.5%
I = .551 10.1 10.1 10.1 10.3 9.4 8.0
(0, 2σ0) 5.0% 5.5% 5.5% 4.6% 5.0% 5.3%
I = 0 38.2 38.2 38.2 30.7 22.1 22.7
(δ/2, 2σ0) 50.3% 50.0% 49.7% 53.8% 44.0% 44.5%
I = .045 38.1 38.2 38.2 30.7 25.5 26.0
(δ, 2σ0) 95.2% 89.1% 91.3% 92.9% 91.9% 91.4%
I = .169 38.1 38.2 38.2 30.7 22.1 20.2
(0, 3σ0) 5.0% 5.3% 5.3% 4.6% 5.1% 5.2%
I = 0 85.2 85.2 85.3 67.7 26.3 26.7
(0, 5σ0) 5.0% 5.4% 5.4% 4.7% 5.2% 5.1%
I = 0 236 235 236 186 27.6 28.6
(0, 10σ0) 5.0% 5.4% 3.8% 4.9% 5.1% 5.1%
I = 0 942 940 943 754 28.7 29.3
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Table 5. Maximum sample size M , power and per-group expected sample size for the tests
L1 and L2 of Li et al., Proschan & Hunsberger (PH), and ADAPT
(µX − µY , σ)
I
L1 L2 PH ADAPT
(0, 1) 5.5% 5.3% 5.5% 4.8%
I = 0 26.3 25.5 25.9 56.5
(0, 2) 5.3% 5.3% 5.4% 5.4%
I = 0 26.2 26.3 25.9 93.5
(1/4, 1) 29.9% 29.3% 29.0% 48.3%
I = .016 32.8 31.0 31.6 76.1
(3/8, 1) 49.5% 48.7% 48.3% 77.5%
I = .035 34.5 32.7 33.1 73.5
(1/2, 1) 67.8% 66.4% 66.4% 92.8%
I = .061 34.3 32.8 32.7 63.3
(1/2, 2) 12.0% 29.9% 28.9% 56.1%
I = .016 29.1 32.9 31.7 98.7
(3/4, 2) 49.8% 48.5% 48.1% 85.6%
I = .035 34.5 32.7 33.2 87.0
µX−µY = 0. Since the conditional power criterion is not valid when the estimated difference
of means is near zero, the L and PH tests must stop for futility when this occurs even though
the true difference of means may be substantially greater than zero.
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3.4 Comparison of Tests Allowing Mid-course Modification of Max-
imum Sample Size
As pointed out in Section 1, Cui et al. (1999) have proposed a method to modify the group
size of a given group sequential test of H0 : θ ≤ 0 in response to protocol amendments during
interim analyses. In the example considered by Cui et al. (1999, p. 854), the maximum
sample size is initially M = 125 for detecting θ1 = .29 with power .9 and α = .025, but can
be subsequently increased up to M˜ = 500; their sample sizes are twice as large because they
consider variance 2. They consider modifying the group size at the end of a given stage L
if the ratio of conditional power at the observed alternative θ̂nL to the conditional power at
θ1 is greater than 1 or less than .8, in which case the group size is then modified so that the
new maximum sample size is
M˜ ∧M(θ1/θ̂nL)2. (3.2)
If (3.2) is less than the already sampled nL, error spending can be used to end the trial.
The crux of this method is that the original critical values can be used for the weighted
test statistic without changing the Type I error probability regardless of how the sample
size is changed. Table 6 compares their proposed adaptive group sequential tests with FSS
tests, standard (non-adaptive) group sequential tests, and the adaptive test described in
Section 2.2. Each result is based on 100,000 simulations. All adaptive tests in Table 6 use the
first-stage sample size m = 25, maximum sample size initially M = 125 with the possibility
of extension up to M˜ = 500, and Type I error probability not exceeding α = .025, matching
the setting considered in Section 2 of Cui et al. (1999). Since the maximum sample size can
vary between M = 125 and M˜ = 500, the two relevant implied alternatives are θ1 = .29,
where FSS125 has power 1− α˜ = .9, and θ2 = .15, where FSS500 has power .9. The values of
the user-specified parameters of the tests in Table 6 are summarized below.
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• ADAPT: The adaptive test, described in Section 2.2, that uses b = 3.48, b˜ = 2.1 and
c = 2.31 corresponding to ε = ε˜ = 1/2, ρm = .1 and M
′ = 250.
• FSS125, FSS500: The FSS tests having sample sizesM = 125 and M˜ = 500, respectively.
• OBF5SC: A one-sided O’Brien-Fleming group sequential test having five groups of size
100 and that uses stochastic curtailment futility stopping (γ = .9 in Section 10.2
of Jennison and Turnbull (2000)) with reference alternative θ2 = .15; see below.
• C4, C5: Two versions the adaptive group sequential test of Cui et al. (1999) that
adjusts the group size at the end of the first stage; C4 uses four stages and C5 uses five
stages.
• C5SC , C5PF : Two modifications of C5 to allow for futility stopping; C5SC uses stochastic
curtailment futility stopping (γ = .9 in Section 10.2 of Jennison and Turnbull (2000))
and C5PF uses power family futility stopping (∆ = 1 in Section 4.2 of Jennison and Turnbull
(2000)). Both C5SC and C
5
PF use reference alternative θ2 = .15.
Since OBF5SC , C
5
SC and C
5
PF have maximum sample size M˜ = 500, the futility stopping
boundaries of these tests are designed to have power .9 at θ2. We have also included C
4
because our adaptive test uses no more than four stages. The tests are evaluated at the θ
values where FSS125 has power .01, .025, .7, .8 and .9, and where FSS500 has power .7, .8
and .9.
Even though the C tests have maximum sample size M˜ = 500, they are underpowered
at 0 < θ ≤ θ2, the alternative implied by M˜ , when compared with ADAPT, FSS500 and
OBF5SC. In particular, the C tests have power less than .65 at θ2. Since C
4 and C5 use no
futility stopping, this suggests that their updated maximum sample size (3.2) (with L = 1)
has contributed to the power loss. The large expected sample sizes of C4 and C5 at θ ≤ 0
reveal another problem with this sample size updating rule: It does not consider the sign of
θ̂m; a negative value of θ̂m could result in the same sample size modification as a positive
one, causing a large increase in the group size when it should be decreased toward futility
stopping. ADAPT has only a slight loss of power in comparison with FSS500 and the five-
stage OBF5SC at θ > 0, with substantially smaller expected sample size. The mean number
of stages of ADAPT at θ1 = .29 shows that it behaves like a two- or three-stage test there.
OBF5SC, on the other hand, has the largest expected sample size at θ ≥ 0 of the tests in
Table 6 other than FSS125.
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4 ASYMPTOTIC THEORYANDAMODIFIED CONDITIONAL
POWER TEST
In this section we prove the asymptotic optimality of the adaptive tests in Sections 2.1 and
2.2. The proof also sheds light on how the two-stage conditional power tests, which are shown
to be severely under-powered in Section 3, can substantially increase their power by adding
a third stage. These modified conditional power tests are still not asymptotically efficient
because they try to mimic the optimal FSS test when the alternative is given whereas the
adaptive test of Section 2.1 tries to mimic the SPRT instead, assuming H0 to be simple.
Theorem 4.1. Let N denote the sample size of the three-stage GLR test in Section 2.1, with
m, M and m ∨ {M ∧ ⌈(1 + ρm)n(θ̂m)⌉} being the possible values of N . Let T be the sample
size of any test of H0 : u(θ) ≤ u0 versus H1 : u(θ) ≥ u1, sequential or otherwise, which takes
at least m and at most M observations and whose Type I and Type II error probabilities do
not exceed α and α˜, respectively. Assume that logα ∼ log α˜,
m/| logα| → a, M/| logα| → A, ρm → 0 but m 12ρm/(logm)1/2 →∞ (4.1)
as α+ α˜→ 0, with 0 < a < A. Then for every fixed θ, as α+ α˜→ 0,
Eθ(N) ∼ m ∨ (M ∧ | logα|/{ inf
λ:u(λ)=u0
I(θ, λ) ∨ inf
λ:u(λ)=u1
I(θ, λ)}), (4.2)
Eθ(T ) ≥ (1 + o(1))Eθ(N). (4.3)
Proof. Let Θ0 = {θ : u(θ) ≤ u0}, Θ1 = {θ : u(θ) ≥ u1}. By (2.1), for i = 0, 1,
inf
λ∈Θi
I(θ, λ) = Ii(θ), where Ii(θ) = inf
λ:u(λ)=ui
I(θ, λ). (4.4)
Take any λ ∈ Θ0 and λ˜ ∈ Θ1. In view of (4.4) and Hoeffding’s (1960) lower bound for the
expected sample size Eθ(T ) of a test that has error probabilities α and α˜ at λ and λ˜ and
takes at least m and at most M observations,
Eθ(T ) ≥ m ∨
{
M ∧ (1 + o(1))| logα|
I0(θ) ∨ I1(θ)
}
(4.5)
as α + α˜ → 0 such that logα ∼ log α˜. We next show that the asymptotic lower bound in
(4.5) is attained by N . Since m ∼ a| logα| and M ∼ A| logα| and since the thresholds b, b˜
and c are defined by (2.7)-(2.9), we can use an argument similar to the proof of Theorem 2(ii)
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of Lai and Shih (2004, p. 525) to show that (4.2) holds. In fact, the second-stage sample
size of the adaptive test is a slight inflation of the Hoeffding-type lower bound (4.5) with θ
replaced by the maximum likelihood estimate θ̂m at the end of the first stage. The assumption
ρm → 0 but ρm ≻ m−1/2(logm)1/2 is used to accommodate the difference between θ and its
substitute θ̂m, noting that as m→∞,
Pθ{
√
m|θ̂m − θ| ≥ r(logm)1/2} = o(m−1)
is r if sufficiently large, by standard exponential bounds involving moment generating func-
tions.
We can now extend the Hoeffding-type lower bound (4.5) to establish the asymptotic
optimality of the adaptive test in Section 2.2 that allows mid-course modification of the
maximum sample size. This adaptive test can be regarded as a mid-course amendment of
an adaptive test of H0 : u(θ) ≤ u0 versus H1 : u(θ) ≥ u1, with a maximum sample size of
M , to that of H0 versus H2 : u(θ) ≥ u2, with a maximum sample size of M˜ . Whereas (4.5)
provides an asymptotic lower bound for tests of H0 versus H1, any test of H0 versus H2 with
error probabilities not exceeding α and α˜ and taking at least m and at most M˜ observations
likewise satisfies
Eθ(T ) ≥ m ∨
{
M˜ ∧ (1 + o(1))| logα|
I0(θ) ∨ I2(θ)
}
(4.6)
as α+α˜→ 0 such that logα ∼ log α˜. Note that Θ1 = {θ : u(θ) ≥ u1} ⊂ Θ2 = {θ : u(θ) ≥ u2}
and therefore I2(θ) ≤ I1(θ). The 4-stage test in Section 2.2, with M ′ = M˜ , attempts to
attain the asymptotic lower bound in (4.5) prior to the third stage and the asymptotic lower
bound in (4.6) afterwards. It replaces I1(θ) in (4.5), which corresponds to early stopping for
futility, by I2(θ) that corresponds to rejection of H2 (instead of H1) in favor of H0. Thus,
the second-stage sample size n2 corresponds to the lower bound in (4.5) with θ replaced by
θ̂m and I1 replaced by I2, while the third-stage sample size corresponds to that in (4.6) with
θ replaced by θ̂n2 . The arguments used to prove the asymptotic optimality of the 3-stage
test in Theorem 4.1 can be readily modified to prove the following.
Theorem 4.2. Let N∗denote the sample size of the four-stage GLR test in Section 2.2, with
M ′ = M˜ . Assume that logα ∼ log α˜ as α + α˜ → 0, that (4.1) holds and M˜/| logα| → A˜
with 0 < a < A < A˜. Then
Eθ(N
∗) ∼
{
m ∨ (1 + o(1))| logα|/I0(θ) if I0(θ) > A−1
m ∨ [M˜ ∧ (1 + o(1))| logα|/{I0(θ) ∨ I2(θ)}] if I0(θ) < A−1.
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The simulation results in Table 5 show that the two-stage tests of Proschan and Hunsberger
(1995) and Li et al. (2002), which use conditional power to determine the second-stage sam-
ple size, have actual power much lower than the adaptive test of Section 2.1. Without
assuming a prespecified alternative θ1, the usual approach in the literature on sample size
re-estimation considers the case d = 1 and u(θ) = θ and determines the second-stage sample
size via the conditional power criterion
n˜(θ) = min{n ≥ m : Pθ(Sn ≥ cα,n|Sm) ≥ 1− α˜}, (4.7)
choosing n2 = n˜(θ̂m) if θ̂m ≥ θ0 + δ and stopping at the first stage due to futility otherwise,
where Pθ0{Sn ≥ cα,n} = α and δ is chosen “to set an upper bound to limit the sample
size of the second stage”; see Li et al. (2002, p. 283). Although the conditional power given
θ̂m ≥ θ0+ δ is at least 1− α˜ by choosing the second-stage sample size to be n˜(θ̂m), the actual
(unconditional) Type II error probability of the test at θ(> θ0) may substantially exceed α˜ if
m is not large enough since Pθ{θ̂m < θ0 + δ} may well exceed α˜. Stopping due to futility at
the end of the first stage when θ̂m < θ0+ δ can lead to serious loss of power of the two-stage
test. By allowing the test to have a possible third stage, we do not have to stop prematurely
when θ̂m falls below θ0, for which the conditional power criterion (4.7) is not applicable.
Thus, a three-stage test that uses conditional power to determine the second-stage sample
size chooses n1 = m, n3 = M and n2 = min{n˜(θ̂m),M}, where n˜(θ) is defined by (4.7) if
θ > θ0, and by
n˜(θ) = max{m, ⌈| log α˜|/I(θ, θ1)⌉} if θ ≤ θ0. (4.8)
The rejection and futility boundaries are given by (2.2)-(2.4) as in the three-stage test of
Section 2.1. The asymptotic properties of the test, whose sample size is denoted by N˜ , are
given by the following.
Theorem 4.3. Define ηθ for θ > θ0 by
θ0 < ηθ < θ and I(ηθ, θ0) = I(ηθ, θ). (4.9)
Then as α+ α˜→ 0, Eθ(N˜) ∼ n˜(θ) if θ < θ0 and
Eθ(N˜) ∼ m ∨ {M ∧ | logα|/I(ηθ, θ0)} if θ > θ0. (4.10)
Proof. Suppose θ > θ0. From (4.1) and the law of large numbers, it follows that Pθ{θ̂m >
θ0} → 1 as α + α˜→ 0, and therefore
Pθ{θ̂m > θ0 and N˜ = n˜(θ̂m) ∧M} → 1. (4.11)
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Since n˜(θ) is given by (4.7) in this case, application of Theorem 2(i) of Lai and Shih (2004)
then yields
n˜(θ) ∼ m ∨ (| logα|/I(ηθ, θ)). (4.12)
In view of (4.1), we can apply Lebesgue’s dominated convergence theorem to obtain (4.10)
from (4.11) and (4.12) in this case. Note in this connection that I(ηθ, θ) is continuous in θ
and that θ̂m converges to θ in probability.
We next consider the case θ < θ0. Then n˜(θ) is given by (4.8), which is less than
M ∼ | logα|/I(θ∗, θ1) as α + α˜ → 0 such that logα ∼ log α˜. By the law of large numbers,
Pθ{θ̂m < θ0 and N˜ = n˜(θ̂m)} → 1. Continuity of I(θ, θ1) and dominated convergence can
then be used to show that Eθ(N˜) ∼ n˜(θ).
Since I(ηθ, θ0) < I(θ, θ0) by (4.9), it follows from (4.2) and (4.10) that the three-stage
test using the conditional power criterion (4.7) is not asymptotically efficient. This is not
surprising since (4.7) is the sample size for the level-α FSS test to have at least 1− α˜ power
at the alternative θ(> θ0). However, the optimal test with error probabilities α at θ0 and α˜
at θ is Wald’s sequential probability ratio test whose expected sample size is of the smaller
order | logα|/I(θ, θ0) under the assumptions of Theorem 4.1.
5 DISCUSSION
A major drawback of the commonly used conditional power approach to two-stage designs
is pointed out in Section 3.3. The actual power can be much lower than the conditional
power since the estimated alternative at the end of the first stage can be quite different from
the actual alternative. In particular, if the estimated alternative falls in the region of the
null hypothesis and misleads one to stop for futility, there can be substantial loss of power.
On the other hand, early stopping for futility is critical for keeping the sample size of a
conditional power test within a manageable bound M . Our three-stage test makes use of
M to come up with an implied alternative which is used to choose the rejection and futility
boundaries appropriately so that the test does not lose much power in comparison with the
(most powerful) fixed sample size test of the null hypothesis versus the implied alternative.
This idea underlying (2.7)-(2.9) that define the stopping boundaries of three-stage tests has
been used earlier by Lai and Shih (2004) to develop efficient group sequential tests.
Our approach estimates the second-stage sample size by using an approximation to Ho-
effding’s lower bound for the expected sample size of sequential tests satisfying a prescribed
Type I error constraint and a Type II error constraint at the alternative that is estimated at
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the end of the first stage. As shown in the simulation studies in Bartroff and Lai (2008) and
in the asymptotic theory in Section 4, this approach yields adaptive tests that are compara-
ble to the benchmark optimal adaptive test of Jennison and Turnbull (2006a,b) for a normal
mean, which assumes known variance and a specified alternative. Our approach can serve
to bridge the gap between the two “camps” in the adaptive design literature: One camp fo-
cuses on efficient designs, under restrictive assumptions, that involve sufficient statistics and
optimal stopping rules, while the other camp emphasizes flexibility to address the difficulty
of coming up with realistic alternatives at the design stage. As pointed out in Section 1,
our approach that is built on the foundations of sequential testing theory is able to resolve
the dilemma between efficiency and flexibility. Like the “efficiency camp,” it adheres to the
GLR test statistics whose efficiency is well established in the theory of FSS tests. An impor-
tant innovation is that it uses the Markov property to compute error probabilities when the
fixed sample size is replaced by a data-dependent sample size that is based on the estimated
alternative at the end of the first stage, like the “flexibility camp.”
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